EICHOR
● Terminated
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
Condition: Prurigo Nodularis · Sponsor: Amgen
About this study
The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PRO) measure of pruritus and overall clinical assessment score (US only).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (192)
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| First OC Dermatology | Fountain Valley, California, United States | — |
| Los Angeles Universal Research Center | Los Angeles, California, United States | — |
| Paradigm Clinical Research Center Inc | San Diego, California, United States | — |
| Wolverine Clinical Trials | Santa Ana, California, United States | — |
| Direct Helpers Research Center | Hialeah, Florida, United States | — |
| Southern Clinical Research | Miami, Florida, United States | — |
| University of Miami Hospital | Miami, Florida, United States | — |
| Miami Dermatology and Laser Institute | Miami, Florida, United States | — |
| Wellness Clinical Research | Miami Lakes, Florida, United States | — |
| Clinical Research Trials of Florida Inc | Tampa, Florida, United States | — |
| Olympian Clinical Research - Tampa | Tampa, Florida, United States | — |
+ 180 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06527404